AI주식인사이트AI Stock Insight
C

에이비엘바이오

298380KOSDAQ

48.3 / 100

Reference Date: 2026-09-08

Financial Score18.5 / 40
News Sentiment16.8 / 25
Momentum3.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 17.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

ABL Bio focuses on a growth-oriented business model through technology licensing (License-out) and joint development based on its dual-antibody platform 'Grabody™'. The company addresses unmet medical needs with global technology transfer cases in areas such as ADCs and immuno-oncology therapies. Its U.S. subsidiary, NEOK Bio, manages ADC clinical trials, and cash inflows from milestone achievements in licensing agreements enhance financial stability.

Number of Employees

108people

Average Salary

125.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
—Industry Average 1.203.5Point
ROE
-23.38Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
0.47Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲44.3% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼1068.4% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -24.4% (declining, 3yr)

Detailed News Sentiment

17 totalPositive 7Neutral 5Negative 5Average Sentiment Score 67.4

Detailed Momentum

52-week position1.0Point

Near 52w low (5%, downtrend)

Current 71,100Won52-week high 245,50052-week low 60,800
1-month return0.0Point

1m -17.90% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0
  • Neutral주식등의대량보유상황보고서(일반)2026-09-04
  • Neutral[기재정정]주식매수선택권부여에관한신고2026-08-31
  • Neutral주식매수선택권부여에관한신고2026-08-26
  • Neutral반기보고서 (2026.06)2026-08-11